While 12.8% of primary recommendations were based on PD-L1 scoring (TPS, ICS and CPS), only one of five patients (PatID 40; a thymoma with a CPS of 91) reached SD on single agent immune checkpoint blockade, while the other four were progressive. This evidence concerns the gene CD274 and thymoma.